Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP)

This article has no abstract
Epistemonikos ID: 6ae03da47b0ec003f30fc3ded25ef6861f6d4357
First added on: Feb 13, 2025